BioSpace News Archive

Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events.

Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug Administration confirmed 13 to 1, with 0 abstention that the benefits of Abbott’s TriClip™ transcatheter edge-to-edge repair system outweighed the risks for the treatment of people with tricuspid regurgitation.

Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers.

Ascentage Pharma announced that it has received clearance from the US Food and Drug Administration to initiate a global registrational Phase III trial of olverembatinib in previously treated adult patients with chronic-phase chronic myeloid leukemia.

Immunome, Inc., a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share.

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2023 on Tuesday, Feb. 20 at 9 a.m., ET.

NewAmsterdam Pharma Company N.V. announced the pricing of the previously announced underwritten public offering of 4,488,159 of the Company’s ordinary shares, with a nominal value of €0.12 per share at a public offering price of $19.00 per share and to certain investors that so choose in lieu of Ordinary Shares.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the first quarter fiscal year 2024 ended December 31, 2023.

Yinuoke, a biopharmaceutical company pioneering breakthrough therapeutics for late-stage cancer patients announced today the publication of a manuscript in the peer-reviewed